A potential coronavirus vaccine developed by Oxford University in the U.K. has produced a strong immune response in a large, early-stage human trial, according to newly released data published Monday in the medical journal The Lancet. Oxford researchers, in partnership with pharmaceutical giant AstraZeneca, are calling their experimental vaccine ChAdOx1 nCoV-19. It combines genetic material from the coronavirus with a modified adenovirus that is known to cause infections in chimpanzees. The phase one trial had more than 1,000 participants. Professor Adrian Hill, director of Oxford University’s Jenner Institute, told ... (full story)

The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by vaccination. We assessed the safety, reactogenicity, and immunogenicity of a viral vectored coronavirus vaccine that expresses the spike protein of SARS-CoV-2. Methods We did a phase 1/2, single-blind, randomised controlled trial in five trial sites in the UK of a chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19) expressing the SARS-CoV-2 spike protein compared with a meningococcal conjugate vaccine (MenACWY) as control. Healthy adults aged 18–55 years with no history of laboratory confirmed SARS-CoV-2 infection ... (full story)